BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 27669236)

  • 1. miR33a/miR33b* and miR122 as Possible Contributors to Hepatic Lipid Metabolism in Obese Women with Nonalcoholic Fatty Liver Disease.
    Auguet T; Aragonès G; Berlanga A; Guiu-Jurado E; Martí A; Martínez S; Sabench F; Hernández M; Aguilar C; Sirvent JJ; Del Castillo D; Richart C
    Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27669236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PNPLA3 Expression Is Related to Liver Steatosis in Morbidly Obese Women with Non-Alcoholic Fatty Liver Disease.
    Aragonès G; Auguet T; Armengol S; Berlanga A; Guiu-Jurado E; Aguilar C; Martínez S; Sabench F; Porras JA; Ruiz MD; Hernández M; Sirvent JJ; Del Castillo D; Richart C
    Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27128907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agonist of RORA Attenuates Nonalcoholic Fatty Liver Progression in Mice via Up-regulation of MicroRNA 122.
    Chai C; Cox B; Yaish D; Gross D; Rosenberg N; Amblard F; Shemuelian Z; Gefen M; Korach A; Tirosh O; Lanton T; Link H; Tam J; Permyakova A; Ozhan G; Citrin J; Liao H; Tannous M; Hahn M; Axelrod J; Arretxe E; Alonso C; Martinez-Arranz I; Betés PO; Safadi R; Salhab A; Amer J; Tber Z; Mengshetti S; Giladi H; Schinazi RF; Galun E
    Gastroenterology; 2020 Sep; 159(3):999-1014.e9. PubMed ID: 32450149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered fatty acid metabolism-related gene expression in liver from morbidly obese women with non-alcoholic fatty liver disease.
    Auguet T; Berlanga A; Guiu-Jurado E; Martinez S; Porras JA; Aragonès G; Sabench F; Hernandez M; Aguilar C; Sirvent JJ; Del Castillo D; Richart C
    Int J Mol Sci; 2014 Dec; 15(12):22173-87. PubMed ID: 25474087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A micro-RNA expression signature for human NAFLD progression.
    Guo Y; Xiong Y; Sheng Q; Zhao S; Wattacheril J; Flynn CR
    J Gastroenterol; 2016 Oct; 51(10):1022-30. PubMed ID: 26874844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting Nonalcoholic Fatty Liver Disease through a Panel of Plasma Biomarkers and MicroRNAs in Female West Virginia Population.
    Pillai SS; Lakhani HV; Zehra M; Wang J; Dilip A; Puri N; O'Hanlon K; Sodhi K
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32933141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepcidin in morbidly obese women with non-alcoholic fatty liver disease.
    Auguet T; Aragonès G; Berlanga A; Martínez S; Sabench F; Binetti J; Aguilar C; Porras JA; Molina A; Del Castillo D; Richart C
    PLoS One; 2017; 12(10):e0187065. PubMed ID: 29065180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice.
    Yamamoto T; Nakade Y; Yamauchi T; Kobayashi Y; Ishii N; Ohashi T; Ito K; Sato K; Fukuzawa Y; Yoneda M
    World J Gastroenterol; 2016 Feb; 22(8):2512-23. PubMed ID: 26937139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The intrahepatic expression levels of bile acid transporters are inversely correlated with the histological progression of nonalcoholic fatty liver disease.
    Okushin K; Tsutsumi T; Enooku K; Fujinaga H; Kado A; Shibahara J; Fukayama M; Moriya K; Yotsuyanagi H; Koike K
    J Gastroenterol; 2016 Aug; 51(8):808-18. PubMed ID: 26601667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased Circulating Levels of Alpha-Ketoglutarate in Morbidly Obese Women with Non-Alcoholic Fatty Liver Disease.
    Aragonès G; Auguet T; Berlanga A; Guiu-Jurado E; Martinez S; Armengol S; Sabench F; Ras R; Hernandez M; Aguilar C; Colom J; Sirvent JJ; Del Castillo D; Richart C
    PLoS One; 2016; 11(4):e0154601. PubMed ID: 27123846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic miR-33a/miR-144 and their target gene ABCA1 are associated with steatohepatitis in morbidly obese subjects.
    Vega-Badillo J; Gutiérrez-Vidal R; Hernández-Pérez HA; Villamil-Ramírez H; León-Mimila P; Sánchez-Muñoz F; Morán-Ramos S; Larrieta-Carrasco E; Fernández-Silva I; Méndez-Sánchez N; Tovar AR; Campos-Pérez F; Villarreal-Molina T; Hernández-Pando R; Aguilar-Salinas CA; Canizales-Quinteros S
    Liver Int; 2016 Sep; 36(9):1383-91. PubMed ID: 26945479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Series of microRNA in the Chromosome 14q32.2 Maternally Imprinted Region Related to Progression of Non-Alcoholic Fatty Liver Disease in a Mouse Model.
    Okamoto K; Koda M; Okamoto T; Onoyama T; Miyoshi K; Kishina M; Kato J; Tokunaga S; Sugihara TA; Hara Y; Hino K; Murawaki Y
    PLoS One; 2016; 11(5):e0154676. PubMed ID: 27135827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating microRNA expression and nonalcoholic fatty liver disease in adolescents with severe obesity.
    Li YJ; Baumert BO; Stratakis N; Goodrich JA; Wu HT; He JX; Zhao YQ; Aung MT; Wang HX; Eckel SP; Walker DI; Valvi D; La Merrill MA; Ryder JR; Inge TH; Jenkins T; Sisley S; Kohli R; Xanthakos SA; Baccarelli AA; McConnell R; Conti DV; Chatzi L
    World J Gastroenterol; 2024 Jan; 30(4):332-345. PubMed ID: 38313232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased lipid metabolism but increased FA biosynthesis are coupled with changes in liver microRNAs in obese subjects with NAFLD.
    Latorre J; Moreno-Navarrete JM; Mercader JM; Sabater M; Rovira Ò; Gironès J; Ricart W; Fernández-Real JM; Ortega FJ
    Int J Obes (Lond); 2017 Apr; 41(4):620-630. PubMed ID: 28119530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adipocytokine expression associated with miRNA regulation and diagnosis of NASH in obese patients with NAFLD.
    Estep JM; Goodman Z; Sharma H; Younossi E; Elarainy H; Baranova A; Younossi Z
    Liver Int; 2015 Apr; 35(4):1367-72. PubMed ID: 24684403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Tanshinone IIA on the modulation of miR‑33a and the SREBP‑2/Pcsk9 signaling pathway in hyperlipidemic rats.
    Jia L; Song N; Yang G; Ma Y; Li X; Lu R; Cao H; Zhang N; Zhu M; Wang J; Leng X; Cao Y; Du Y; Xu Y
    Mol Med Rep; 2016 Jun; 13(6):4627-35. PubMed ID: 27082100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma phospholipids and fatty acid composition differ between liver biopsy-proven nonalcoholic fatty liver disease and healthy subjects.
    Ma DW; Arendt BM; Hillyer LM; Fung SK; McGilvray I; Guindi M; Allard JP
    Nutr Diabetes; 2016 Jul; 6(7):e220. PubMed ID: 27428872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids.
    Arendt BM; Comelli EM; Ma DW; Lou W; Teterina A; Kim T; Fung SK; Wong DK; McGilvray I; Fischer SE; Allard JP
    Hepatology; 2015 May; 61(5):1565-78. PubMed ID: 25581263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deregulated hepatic microRNAs underlie the association between non-alcoholic fatty liver disease and coronary artery disease.
    Braza-Boïls A; Marí-Alexandre J; Molina P; Arnau MA; Barceló-Molina M; Domingo D; Girbes J; Giner J; Martínez-Dolz L; Zorio E
    Liver Int; 2016 Aug; 36(8):1221-9. PubMed ID: 26901384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease.
    Tai CM; Huang CK; Tu HP; Hwang JC; Chang CY; Yu ML
    Surg Obes Relat Dis; 2015; 11(4):888-94. PubMed ID: 25240529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.